EFFECTS OF ZOLEDRONIC ACID ON OOFORECTOMIZED RATS' TIBIAE: A PROSPECTIVE AND RANDOMIZED STUDY

Overview

Journal Rev Bras Ortop

Specialty Orthopedics

Date 2016 Mar 22

PMID 26998455

Citations 2

Authors

Fernando Roberto Alves Pereira

Ricardo Cesar Dutra

Thiago Cesar Reis Olimpio

Sergio Swain Muller

Evandro Pereira Palacio

Affiliations

Soon will be listed here.

Abstract

Unlabelled: To investigate clinical, biomechanic and histomorphometric effects of zoledronic acid on osteoporotic rats' tibiae after bilateral ooforectomy.

Methods: 40 female Wistar (Rattus novergicus albinus) rats were prospectively studied. On the 60th day of life, the animals were randomized into two groups according to the surgical procedure: bilateral ooforectomy (O) (n=20) and sham surgery ("sham") (P) (n=20). After 30 days, the animals were divided into four groups, according to the administration of zoledronic acid (ZA) 0.1mg/kg or distilled water (DW): OZA (n=10), ODW (n=10), PZA (n=10) and PDW (n=10). After 12 months, the animals were sacrificed, and had their tibiae assessed. In the clinical study, animals' weight was considered; in the biomechanical study, compressive assays were applied and, in the histomorphometric analysis, the bone trabecular area was determined.

Results: "O" groups showed a significantly greater weight gain than "P" groups (p=0.005). Groups OZA and PZA showed an insignificant weight gain when compared to ODW (p=0.47) and PDW (p=0.68). The groups receiving zoledronic acid and distilled water were able to bear maximum load, similar (p=0.2), at the moment of fracture. In the groups receiving zoledronic acid, an insignificant increase of the bone trabecular area was found when compared to the groups receiving distilled water (p=0.21). There was a positive correlation between trabecular area and maximum load (p=0.04; r=0.95).

Conclusion: Zoledronic acid did not significantly influence animals' weight. The results showed an insignificant increase both of the tibial shaft bone resistance and the bone trabecular area.

Citing Articles

The effects of ethyl-2-cyanoacrylate and butyl-2-cyanoacrylate in the process of bone healing in rats. A controlled experimental study.

Palacio E, Pereira G, de Almeida Silvares P, Stasi G, Staut C, Sardenberg T Rev Bras Ortop. 2018; 53(1):53-59.

PMID: 29367907 PMC: 5771781. DOI: 10.1016/j.rboe.2017.11.010.

Detecting early biomechanical effects of zoledronic Acid on femurs of osteoporotic female rats.

Palacio E, Muller S, Sardenberg T, Mizobuchi R, Galbiatti J, Durigan Jr A J Osteoporos. 2013; 2012:162806.

PMID: 23304634 PMC: 3529494. DOI: 10.1155/2012/162806.

References

Wise L, Waldman S, Kasra M, Cheung R, Binnington A, Kandel R . Effect of zoledronate on bone quality in the treatment of aseptic loosening of hip arthroplasty in the dog. Calcif Tissue Int. 2005; 77(6):367-75. DOI: 10.1007/s00223-005-0062-3. View

Walter C, Grotz K, Kunkel M, Al-Nawas B . Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer. 2006; 15(2):197-202. DOI: 10.1007/s00520-006-0120-z. View

Riggs B, Melton 3rd L . Involutional osteoporosis. N Engl J Med. 1986; 314(26):1676-86. DOI: 10.1056/NEJM198606263142605. View

Patlas N, Zadik Y, Yaffe P, Schwartz Z, Ornoy A . Oophorectomy-induced osteopenia in rats in relation to age and time postoophorectomy. Cells Tissues Organs. 2000; 166(3):267-74. DOI: 10.1159/000016740. View

Shapiro J, Smith B, Beck T, Ballard P, Dapthary M, BrintzenhofeSzoc K . Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury. Calcif Tissue Int. 2007; 80(5):316-22. DOI: 10.1007/s00223-007-9012-6. View

Smith E, Raab D . Osteoporosis and physical activity. Acta Med Scand Suppl. 1986; 711:149-56. DOI: 10.1111/j.0954-6820.1986.tb08944.x. View

Huang T, Lin S, Chang F, Hsieh S, Liu S, Yang R . Effects of different exercise modes on mineralization, structure, and biomechanical properties of growing bone. J Appl Physiol (1985). 2003; 95(1):300-7. DOI: 10.1152/japplphysiol.01076.2002. View

Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M . Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Ann Hematol. 2006; 86(1):23-30. DOI: 10.1007/s00277-006-0180-7. View

Matos M, Araujo F, Paixao F . The effect of zoledronate on bone remodeling during the healing process. Acta Cir Bras. 2007; 22(2):115-9. DOI: 10.1590/s0102-86502007000200007. View

10.

Nguyen T, Blangero J, Eisman J . Genetic epidemiological approaches to the search for osteoporosis genes. J Bone Miner Res. 2000; 15(3):392-401. DOI: 10.1359/jbmr.2000.15.3.392. View

11.

Hornby S, Evans G, Hornby S, Pataki A, GLATT M, Green J . Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats. Calcif Tissue Int. 2003; 72(4):519-27. DOI: 10.1007/s00223-002-2015-4. View

12.

Amanat N, McDonald M, Godfrey C, Bilston L, Little D . Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res. 2007; 22(6):867-76. DOI: 10.1359/jbmr.070318. View

13.

Griz L, Colares V, Bandeira F . [Treatment of Paget's disease of bone: importance of the zoledronic acid]. Arq Bras Endocrinol Metabol. 2006; 50(5):845-51. DOI: 10.1590/s0004-27302006000500004. View

14.

Gilfillan C, Strauss B, Rodda C, Bowden D, Kean A, Obaid M . A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcif Tissue Int. 2006; 79(3):138-44. DOI: 10.1007/s00223-006-0314-x. View

15.

Smith B, Livesay G, Woo S . Biology and biomechanics of the anterior cruciate ligament. Clin Sports Med. 1993; 12(4):637-70. View

16.

Reid I, Brown J, Burckhardt P, Horowitz Z, Richardson P, Trechsel U . Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002; 346(9):653-61. DOI: 10.1056/NEJMoa011807. View

17.

da Paz L, Jorgetti V, Yoshinari N . [Animal models of osteoporosis]. Rev Hosp Clin Fac Med Sao Paulo. 1997; 52(2):86-9. View

18.

Amanat N, Brown R, Bilston L, Little D . A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J Orthop Res. 2005; 23(5):1029-34. DOI: 10.1016/j.orthres.2005.03.004. View

19.

Otrock Z, Azar S, Shamseddeen W, Habr D, Inati A, Koussa S . Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol. 2006; 85(9):605-9. DOI: 10.1007/s00277-006-0136-y. View

20.

Dunford J, Thompson K, Coxon F, Luckman S, Hahn F, Poulter C . Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001; 296(2):235-42. View